Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 4Healthy Participants 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Cirrhosis 1Leiomyosarcoma 1Drug-drug Interaction,SHR3680 1Breast Neoplasms 1Advanced Solid Malignancies 1

Interventions

Injections 12pembrolizumab 11Nivolumab 9Paclitaxel 8senaparib 7Docetaxel 7Cisplatin 6Capecitabine 6Gemcitabine 5toripalimab 4tislelizumab 4atezolizumab 4Ipilimumab 4Carboplatin 4Bevacizumab 4sintilimab 3Rifampin 3Oxaliplatin 3Itraconazole 3130-nm albumin-bound paclitaxel 3zimberelimab 2pertuzumab 2osimertinib 2ontuxizumab 2navoximod 2magrolimab 2fluzoparib 2famitinib 2durvalumab 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor × Digoxin × Clear all
NCT05357911 2024-11-21

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

Nuvation Bio Inc.

Phase 1 Completed
16 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡